Nithin Sashidharan1, Smita Shenoy2, Meena Kumari Kamal Kishore3, Harish Thanusubramanian4. 1. Assistant Professor, Department of Pharmacology, Srinivas Institute of Medical Sciences , Mukka, Mangalore, Karnataka, India . 2. Additional Professor, Department of Pharmacology, Kasturba Medical College, Manipal University , Manipal, Karnataka, India . 3. Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University , Manipal, Karnataka, India . 4. Tutor, Department of Pharmacology, Kasturba Medical College, Manipal University , Manipal, Karnataka, India.
Abstract
BACKGROUND: Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario. AIM: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. SETTINGS AND DESIGN: Observational Study conducted in tertiary care centre. MATERIALS AND METHODS: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. STATISTICAL ANALYSIS: Primarily Descriptive. RESULTS: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. CONCLUSION: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.
BACKGROUND:Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario. AIM: To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. SETTINGS AND DESIGN: Observational Study conducted in tertiary care centre. MATERIALS AND METHODS: The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. STATISTICAL ANALYSIS: Primarily Descriptive. RESULTS: There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. CONCLUSION: Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.
Authors: S Vincent Rajkumar; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; Susan M Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; Morie A Gertz Journal: Blood Date: 2005-08-23 Impact factor: 22.113
Authors: Francesca Gay; Suzanne R Hayman; Martha Q Lacy; Francis Buadi; Morie A Gertz; Shaji Kumar; Angela Dispenzieri; Joseph R Mikhael; P Leif Bergsagel; David Dingli; Craig B Reeder; John A Lust; Stephen J Russell; Vivek Roy; Steven R Zeldenrust; Thomas E Witzig; Rafael Fonseca; Robert A Kyle; Philip R Greipp; A Keith Stewart; S Vincent Rajkumar Journal: Blood Date: 2009-12-11 Impact factor: 22.113
Authors: Heinz Ludwig; Roman Hajek; Elena Tóthová; Johannes Drach; Zdenek Adam; Boris Labar; Miklós Egyed; Ivan Spicka; Heinz Gisslinger; Richard Greil; Ingrid Kuhn; Niklas Zojer; Axel Hinke Journal: Blood Date: 2008-10-27 Impact factor: 22.113
Authors: Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp Journal: Mayo Clin Proc Date: 2003-01 Impact factor: 7.616